DBV TECHNOLOGIES news, videos and press releases - Page 7
For more news please use our advanced search feature.
DBV TECHNOLOGIES - More news...
DBV TECHNOLOGIES - More news...
- DBV Technologies Reports March 31, 2018 Cash Position
- Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products — Discovering Underlying Factors of Influence
- DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies to Attend the 11th Kempen Life Sciences Conference
- DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
- DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
- DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
- DBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F
- DBV Technologies Reports Full Year 2017 Financial Results
- DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies to Present at the Barclays Global Healthcare Conference
- DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
- DBV Technologies Reports December 31, 2017 Cash Position
- DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut
- DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies présente de nouveaux résultats lors du Congrès Annuel 2018 de l'AAAAI/WAO concernant sa plateforme Viaskin
- DBV Technologies to Attend Upcoming Investor Conferences
- Half-Year Report on DBV Technologies Liquidity Contract with Natixis
- DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference
- DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & E...
- DBV Technologies to Attend Citi's 2017 Global Healthcare Conference
- DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients
- DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association
- DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company
- DBV Technologies Reports September 30, 2017 Cash Position
- DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
